<DOC>
	<DOCNO>NCT00693992</DOCNO>
	<brief_summary>This randomized phase III trial study sunitinib malate see well work give maintenance therapy ( mean approve treatment chemotherapy ) patient stage IIIB-IV non-small cell lung cancer respond prior treatment combination chemotherapy . Sunitinib malate may stop growth tumor cell block enzymes need cell growth block growth new blood vessel necessary tumor growth . It yet know whether sunitinib malate effective help tumor continue shrink stop growing .</brief_summary>
	<brief_title>Sunitinib Malate Maintenance Therapy Treating Patients With Stage III Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate effect sunitinib ( sunitinib malate ) compare placebo progression-free survival ( PFS ) advance non-small cell lung cancer ( NSCLC ) patient either stable respond disease course initial 4 cycle platinum-based therapy . SECONDARY OBJECTIVES : I . To evaluate toxicity sunitinib compare placebo maintenance setting . II . To evaluate additional response rate result sunitinib setting . III . To assess impact sunitinib overall survival compare placebo arm . IV . To assess impact sunitinib delaying time deterioration quality life symptom progression compare placebo use European Organization Research Treatment Cancer ( EORTC ) Core Quality Life Questionnaire ( QLQ-C30 ) Lung Cancer Module ( LC13 ) . V. To assess vascular endothelial growth factor ( VEGF ) haplotypes advanced non-small cell lung cancer sunitinib maintenance . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive sunitinib malate orally ( PO ) daily ( QD ) day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . ARM II : Patients receive placebo PO QD day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year , every 6 month 1 year , periodically 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologic cytologic documentation primary nonsmall cell lung cancer Stage IIIB IV disease patient candidate combine modality therapy ( chemoradiotherapy ) No evidence symptomatic untreated brain metastasis , spinal cord compression , carcinomatous meningitis ; patient central nervous system ( CNS ) metastases must asymptomatic , must receive definitive therapy ( &gt; = 6 week since resection &gt; = 2 week since radiotherapy ) brain metastasis , steroid stable dose 2 week prior registration No cavitary lesion Patients must receive one chemotherapy regimen stage IIIB IV NSCLC ; regimen must include four cycle platinumbased doublet chemotherapy without bevacizumab ( bevacizumab may give beyond fourth cycle chemotherapy ) ; patient must achieve complete response , partial response , stable disease firstline chemotherapy evidence disease progression ; patient register 35 week follow day 1 cycle 4 prior therapy No prior adjuvant chemotherapy stage IIII resect NSCLC combine modality therapy stage III NSCLC No primary therapy ( include experimental therapy ) NSCLC ; palliative radiation therapy must complete least one week plan start protocol therapy Patients must measurable nonmeasurable disease Measurable disease : lesion accurately measure least one dimension ( long diameter record ) &gt; = 2 cm conventional technique &gt; = 1 cm spiral compute tomography ( CT ) scan Nonmeasurable disease : lesion , include small lesion ( long diameter &lt; 20 mm conventional technique &lt; 10 mm spiral CT scan ) truly nonmeasurable lesion ; lesion consider nonmeasurable include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Nonpregnant nonnursing No ongoing cardiac dysrhythmias , atrial fibrillation , history correct QT ( QTc ) interval &gt; = 500 msec ( within 2 year prior registration ) ; use agent proarrhythmic potential ( e.g. , quinidine , procainamide , disopyramide , sotalol , probucol , haloperidol , risperidone , indapamide , flecainide ) recommend protocol therapy Patients class I New York Heart Association ( NYHA ) heart failure eligible ; patient history class II NYHA heart failure eligible , provided meet least one follow criterion : Patients history class II heart failure asymptomatic treatment Patients prior anthracycline exposure Patients receive central thoracic radiation include heart radiotherapy port Patients history class III IV NYHA heart failure within 12 month prior registration eligible No myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft stenting , cerebrovascular accident transient ischemic attack within last year Patients hypertension control medication ( &gt; 150/100 mmHg despite optimal medical therapy ) eligible Patients require use therapeutic anticoagulation thromboembolic disease eligible ; Note : low dos coumadin ( 2 mg daily ) permit prophylaxis thrombosis No history venous thrombosis , pulmonary embolism , hypercoagulopathy syndrome No history pulmonary hemorrhage , bleed diathesis , evidence hemoptysis ; patient bloodtinged bloodstreaked sputum permit study hemoptysis amount less 5 ml blood per episode le 10 ml blood per 24hour period best estimate investigator Patients history hypothyroidism eligible , provide currently euthyroid None follow within 28 day begin treatment : abdominal fistula , gastrointestinal perforation , intraabdominal abscess , serious nonhealing wound , ulcer , bone fracture The following inhibitor cytochrome P450 3A4 ( CYP3A4 ) prohibit within 7 day begin treatment sunitinib : azole antifungal ( ketoconazole , itraconazole ) , diltiazem , clarithromycin , erythromycin , verapamil , delavirdine , human immunodeficiency virus [ HIV ] protease inhibitor ( indinavir , saquinavir , ritonavir , atazanavir , nelfinavir ) ; follow inducer CYP3A4 prohibit within 12 day begin treatment sunitinib : rifampin , rifabutin , carbamazepine , phenobarbital , phenytoin , St. John 's Wort , efavirenz , tipranavir ; inhibitor inducer CYP3A4 may use necessary , use discouraged Patients unable take oral medication eligible Granulocytes &gt; = 1,500/mcl Platelet count &gt; = 100,000/mcl Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 x ULN ; patient liver metastasis may AST ALT = &lt; 5 x ULN ; patient AST ALT = &lt; 2.5 x ULN Creatinine = &lt; 1.5 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>